Shares of Insys Therapeutics Inc. (NASDAQ:INSY) were down 4.5% during mid-day trading on Tuesday . The stock traded as low as $15.12 and last traded at $15.19, with a volume of 278,186 shares. The stock had previously closed at $15.91.

Several analysts have recently issued reports on INSY shares. Janney Montgomery Scott started coverage on shares of Insys Therapeutics in a research note on Thursday, April 14th. They issued a “buy” rating and a $22.00 target price for the company. Zacks Investment Research upgraded shares of Insys Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 target price for the company in a research note on Wednesday, June 29th. Piper Jaffray Cos. reduced their target price on shares of Insys Therapeutics from $46.00 to $28.00 and set an “overweight” rating for the company in a research note on Monday, April 11th. Royal Bank Of Canada reiterated an “outperform” rating and issued a $32.00 target price (down previously from $44.00) on shares of Insys Therapeutics in a research note on Tuesday, April 12th. Finally, Oppenheimer Holdings Inc. reiterated a “hold” rating on shares of Insys Therapeutics in a research note on Tuesday, April 12th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $23.83.

The company has a 50 day moving average of $14.26 and a 200 day moving average of $15.89. The company has a market cap of $1.09 billion and a price-to-earnings ratio of 21.97.

In related news, major shareholder John N. Kapoor Trust Dated Sept acquired 50,000 shares of the firm’s stock in a transaction on Thursday, May 12th. The stock was acquired at an average cost of $12.84 per share, for a total transaction of $642,000.00. Following the acquisition, the insider now owns 31,982 shares of the company’s stock, valued at $410,648.88. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Theodore H. Stanley sold 16,000 shares of the company’s stock in a transaction on Monday, June 6th. The stock was sold at an average price of $16.27, for a total transaction of $260,320.00. Following the completion of the transaction, the director now owns 18,000 shares of the company’s stock, valued at $292,860. The disclosure for this sale can be found here.

Several hedge funds have added to or reduced their stakes in INSY. Globeflex Capital L P increased its stake in Insys Therapeutics by 99,000.0% in the fourth quarter. Globeflex Capital L P now owns 39,640 shares of the specialty pharmaceutical company’s stock worth $1,135,000 after buying an additional 39,600 shares in the last quarter. California State Teachers Retirement System increased its stake in Insys Therapeutics by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 43,625 shares of the specialty pharmaceutical company’s stock worth $1,249,000 after buying an additional 754 shares in the last quarter. Airain ltd acquired a new stake in Insys Therapeutics during the fourth quarter worth $1,309,000. Bank of Montreal Can increased its stake in Insys Therapeutics by 9.4% in the fourth quarter. Bank of Montreal Can now owns 66,646 shares of the specialty pharmaceutical company’s stock worth $1,909,000 after buying an additional 5,733 shares in the last quarter. Finally, California Public Employees Retirement System increased its stake in Insys Therapeutics by 178.7% in the fourth quarter. California Public Employees Retirement System now owns 97,000 shares of the specialty pharmaceutical company’s stock worth $2,777,000 after buying an additional 62,200 shares in the last quarter.

Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.